NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
10 trialsNCT03711279 2024-02-29
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT05189483 2024-02-07
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
Henan Cancer Hospital
Phase 2 Unknown
NCT06074692 2023-10-31
PRIMA
Ruijin Hospital
Phase 2 Recruiting
NCT04074564 2023-10-23
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase EARLY_PHASE1 Unknown
NCT04910126 2021-06-02
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04606108 2020-10-28
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT04447274 2020-06-25
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
ChineseAMS
Phase 2 Unknown
NCT04239443 2020-01-27
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
Hunan Cancer Hospital
Phase 2 Unknown
NCT04126993 2019-10-15
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown